Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.79 is 56% above its 5-year average of -1.82, near the high end of its 5-year range (-2.33–-0.79).
46.80% above its 12-month average of -1.48.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.14.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.79
EARNINGS PER SHARE (EPS) AVG TTM
-1.48
EARNINGS PER SHARE (EPS) AVG 3Y
-1.81
EARNINGS PER SHARE (EPS) AVG 5Y
-1.82
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+46.80%
CURRENT VS 3Y AVG
+56.47%
CURRENT VS 5Y AVG
+56.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Prelude Therapeutics Incorporated
Market Cap
$216.91M
Earnings Per Share (EPS)
-0.79
TTM Avg
-1.48
3Y Avg
-1.81
5Y Avg
-1.82
Market Cap
$218.30M
Earnings Per Share (EPS)
-3.22
TTM Avg
-1.33
3Y Avg
-3.00
5Y Avg
-2.91
Market Cap
$215.07M
Earnings Per Share (EPS)
N/A
TTM Avg
0.11
3Y Avg
0.08
5Y Avg
0.07
Market Cap
$214.46M
Earnings Per Share (EPS)
-2.18
TTM Avg
-1.64
3Y Avg
-1.32
5Y Avg
-1.32
Market Cap
$214.24M
Earnings Per Share (EPS)
0.19
TTM Avg
0.17
3Y Avg
0.00
5Y Avg
-0.12
Market Cap
$220.93M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.25
3Y Avg
-1.31
5Y Avg
-1.33
Market Cap
$210.98M
Earnings Per Share (EPS)
-11.77
TTM Avg
-8.68
3Y Avg
-4.76
5Y Avg
-3.49
Market Cap
$210.41M
Earnings Per Share (EPS)
-3.97
TTM Avg
-0.86
3Y Avg
-1.18
5Y Avg
-1.19
Market Cap
$209.91M
Earnings Per Share (EPS)
0.38
TTM Avg
0.11
3Y Avg
-0.10
5Y Avg
-0.19
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $216.91M | -0.79 | -1.48 | -1.81 | -1.82 |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | -3.22 | -1.33 | -3.00 | -2.91 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | 0.11 | 0.08 | 0.07 |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -2.18 | -1.64 | -1.32 | -1.32 |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 0.19 | 0.17 | 0.00 | -0.12 |
| Profound Medical Corp. (PROF)vs › | $220.93M | -0.99 | -1.25 | -1.31 | -1.33 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -11.77 | -8.68 | -4.76 | -3.49 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -3.97 | -0.86 | -1.18 | -1.19 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 0.38 | 0.11 | -0.10 | -0.19 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | -0.45 | -0.52 | -0.50 | -0.51 |
Trailing EPS (TTM)
$-0.79
Forward EPS (Est.)
$-0.78
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.29 |
| 2024-12-31 | -1.68 |
| 2023-12-31 | -2.02 |
| 2022-12-31 | -2.27 |
| 2021-12-31 | -2.33 |
| 2020-12-31 | -1.30 |
| 2019-12-31 | -0.85 |
| 2018-12-31 | -9.31 |
